Background The rediscovery of 5-hydroxymethylcytosine, the ten-eleven translocation (TET) family, thymine-DNA glycosylase (TDG) and isocitrate dehydrogenase (IDH) have opened new avenues in the study of DNA demethylation pathways in gastric cancer (GC). We performed a comprehensive and robust analysis of these genes and modified cytosines in gastric cancer. Methods Liquid chromatography mass spectrometry/ mass spectrometry (LC-MS/MS) was used to assess 5-methyldeoxycytidine (5-mC), 5-hydroxymethyldeoxycytidine (5-hmC), 5-formyldeoxycytidine (5-fC) and 5-carboxyldeoxycytidine (5-caC) quantitatively in tumorous and non-tumorous regions of GCs; [D 2 ]-5-hmC was used as an internal standard. Expression levels of the genes TET1, TET2, TET3, TDG, IDH1 and IDH2 were measured using a real-time reverse transcription polymerase chain reaction (RT-PCR) and were compared to the clinical attributes of each case. Using HEK293T cells the effects of introducing plasmids containing full-length TET1, TET2, and TET3 and 7 variants of the TET2 catalytic domain were evaluated in terms of their effect on cytosine demethylation. Results LC-MS/MS showed that 5-hmC was significantly decreased in tumorous portions. 5-mC was also moderately decreased in tumors, while 5-fC and 5-caC were barely detectable. The expressions of TET1, TET2, TET3, TDG and IDH2, but not IDH1, were notably decreased in GCs, compared with the adjacent non-tumor portion. TET1 
Introduction
The ten-eleven translocation (TET) family proteins (TET1, TET2 and TET3) are responsible for the oxidation of 5-methylcytosine (5-mC) in DNA to 5-hydroxymethylcytosine (5-hmC) and the further oxidation of 5-hmC to 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-caC), which are then cleaved from the DNA using thymine-DNA glycosylase (TDG) to be replaced with unmethylated cytosine [1] [2] [3] [4] . Additionally, the oxidation reaction of TET proteins is dependent on Fe 2? and 2-oxoglutarate (2-OG), and 2-OG is dependent on the activity of isocitrate dehydrogenase IDH1 and IDH2 [5, 6] ( Figure S1 ). The loss of 5-hydroxymethylcytosine and the down-regulation of the TET family and IDH2 have been found in human cancers [7] [8] [9] [10] [11] , but comprehensive evaluations of the modified cytosines and the enzymes that are involved have remained largely unperformed and most previous studies have used dot blot analyses as a means of measuring 5-hydroxymethyldeoxycytidine (5-hmC), which is at best a semi-quantitative method. Because dot blot analysis is based on the antigen-antibody reaction direct assessments of the absolute amount of 5-mC, 5-hmC, 5-fC, and 5-caC are not possible. Moreover, since the signal intensities of dot blot images become easily saturate, the standard curve used in the analyses is not linear [12] . In contrast to dot blot analysis, liquid chromatography coupled with tandem mass spectrometry (LC-MS/ MS) can calculate the absolute quantity of the modifications and its standard curve is completely linear. Therefore, LC-MS/MS has greater sensitivity than dot blot analysis. Hence, we established an assay system using LC-MS/MS using a stable isotope standard to measure 4 modified deoxycytidines at the same time and these values were compared to the expression profiles of TET1-3, TDG and IDH1-2.
In this study we applied LC-MS/MS to assess 5-caC, 5-fC, 5-hmC and 5-mC in the genomic DNA of tumor portions and the corresponding non-tumor portions of gastric cancer (GC) samples. TET1-3, TDG and IDH1-2 were quantitated using a real-time reverse transcriptionpolymerase chain reaction (RT-PCR). Next the coding exons of TET1-3 were analyzed by sequencing to search for possible somatic (tumor-specific) mutations and polymorphisms with neural or unknown functionality. Then we analyzed the effect of 5-mC oxidation in vitro by the introduction of TET1-3 and 7 TET2 variants into immortalized human embryonic kidney cells (HEK293T).
Materials and methods
Tissue samples and patients GC tissues and the corresponding adjacent non-tumorous tissues from a total of 58 sporadic GC cases were obtained from the Hamamatsu University Hospital in Japan. The mean patient age was 66.9 years (SD 11.9 years) and the patients included 35 men and 23 women with 26 intestinal and 32 diffuse histological types. All cases were clinically operable and the stages ranged from I to III (no stage IV cases were included). Resected tissues, which were verified as tumorous regions ([70 %) or non-tumorous regions (no contamination with tumor cells) under a microscope by attending pathologists, were snap-frozen in liquid nitrogen and stored at -80°C until used for the isolation of DNA and RNA. Histological classifications were based on the Japanese Classification of Gastric Carcinoma [13] and Lauren's classification [14] was applied when the cases were categorized into two types.
For comparison 5 pairs of gastric cancers and matched normal tissues from ''Gan mice'' (K19-Wnt1/C2mE), a kind gift of Prof. Masanobu Oshima at the Kanazawa University, were also used to measure these cytosine modifications in a non-human model of gastric cancer [15] . The project was approved by the Institutional Review Board of the Hamamatsu University School of Medicine (23-91).
Synthesis of stable isotope-labeled hmC and standard chemicals
Stable isotope-labeled 5-hydroxymethyl-2 0 -deoxycytidine ([D 2 ]-5-hmC) was synthesized from commercially available 5-iodo-2 0 -deoxycytidine (TCI, Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) according to the literature [16] . 5-caC was also synthesized from commercially available 5-iodo-2 0 -deoxycytidine according to a previously reported protocol [17, 18] . 5-fC and 5-hmC were also synthesized from commercially available 5-mC (TCI) according to a previously reported protocol [19] .
DNA purification and hydrolysis for LC-MS/MS
Genomic DNA was isolated and purified from samples of human gastric cancer. Approximately 100 mg of samples were homogenized with 600 ll of lysis solution (10 mM Tris-HCl [pH 8.0], 5 mM EDTA, 0.5 % SDS, and 0.01 % deferoxamine mesylate) using a Physcotron Handy Homogenizer NS-310EII (Microtech nichion, Chiba, Japan) at 15,000 rpm for 2 min. The homogenates were treated with 15 ll of protease K (QIAGEN, CA, USA) at 55°C for 3 h and 15 ll of RNase A (QIAGEN) at 37°C for 40 min. Two hundred microliters of protein precipitation solution (1 mM EDTA, 8 M ammonium acetate, 0.01 % deferoxamine mesylate) was added to the mixture followed by centrifugation at 14,000 g in room temperature for 5 min to remove proteins. Six hundred microliters of isopropanol was added to the supernatant and then centrifuged at 14,000 g in room temperature for 5 min to precipitate the genomic DNA. Precipitates were washed with 70 % ethanol and dried using a Speed-Vac concentrator (Savant, NY, USA). The dried genomic DNA was hydrated with distilled water at the concentration of about 1 mg/ml. Five micrograms of genomic DNA were treated with 50 U of DNaseI (New England Biosystems, MA, USA) for 30 min at 37°C. After incubation 5 lg of phosphodiesterase I, 10 U of calf intestinal alkaline phosphatase (TaKaRa, Kyoto, Japan) and 10 ng of [D 2 ]-5-hmC were added to the mixture. After 1 h of incubation at 37°C the proteins were removed using Nanosep 3K Omega (Pall Corp., MI, USA) by centrifugation at 14,000 g in 4°C for 20 min. Digested samples were stored at -30°C until used for LC-MS/MS analysis.
Quantification using LC-MS/MS
LC-MS/MS analyses were performed using a 4000 QTRAP mass spectrometer with an Acquity TM Ultra Performance LC system (AB SCIEX Instruments, Foster City, CA, USA). Digested DNA was injected and separated using an Acquity UPLC HSS T3 column (2.1 mm 9100 mm; Waters, Milford, CT, USA). The column was eluted as follows: deoxycytidine (C) and 5-mC were eluted in 94 % B from 0 to 3 min and in a linear gradient of 6-60 % B from 3 to 8 min at 0.2 mL/min; 5-hmC was eluted in 6 % B from 0 to 3 min and 20 % B from 3 to 8 min at 0.2 mL/min (mobile phase A: 0.02 % (v/v) acetic acid in water; mobile phase B: methanol); and 5-fC and 5-caC were eluted in 94 % B from 0 to 3 min and in a linear gradient of 6-20 % B from 3 to 10 min at 0.2 mL/min. Multi-reaction monitoring was performed in positive ion mode using nitrogen as the nebulizing gas. Experimental conditions were as follows: ion source temperature, 400°C; cone voltage, 5500 V; collision gas, nitrogen. Collision energies and characteristic reactions were as follows (collision energy (Table  S1 ). excluded from subsequent analyses because we could not detect any signal peaks above the detection limits. The resulting calibration curve was used to determine the global levels of C, 5-mC and 5-hmC in 28 pairs of GC tissues. The 5-mC and 5-hmC values were quantified with reference to the quantity of C. As shown in Table S2 4 C in the normal tissues and 366.66/10 4 C in the cancer tissues, while the median 5-hmC value was 9.63/ 10 4 C in the normal tissues and 3.32/10 4 C in the cancer tissues. In total 5-mC was moderately decreased in the tumor portions compared with the normal portions (Table  S2 , P = 0.021). 5-hmC was strikingly decreased in the tumor portions of the GC cases (Table S2 , P \ 0.001). The reduction of 5-hmC in the tumor portion was correlated with the N classification ( Table 1 , P = 0.018). No correlation was seen between the reduction of 5-mC in the tumor portion and any of the clinicopathological factors that were examined (Table 1) .
For comparison, in terms of the reduction of 5-hmC in the tumor portion, we also performed the same analysis using 5 pairs of gastric cancers and adjacent gastric mucosa from the so-called Gan mouse (K-19-Wnt1/C2mE mouse), which has been established as an inflammation-mediated rodent stomach cancer model [15] . The number of samples that were examined was too small for differences in the 5-mC and 5-hmC values between the tumor portion and the non-tumor portion to reach a statically significant level. However, the 5-hmC level seemed to be lower in the tumorous portion ( Figure S3 ).
Quantification of TET1-3, TDG and IDH1-2 transcripts in GCs
Expressions of TET1-3, TDG and IDH2 were significantly decreased in the tumor portions of the GC cases compared to the corresponding non-tumor tissue (Fig. 1, TET1 , P = 0.004; TET2, P = 0.000295; TET3, P = 0.041; TDG, P = 0.006; IDH2, P = 0.000475) while the expression of IDH1 was not significantly decreased (P = 0.936). Down-regulation of TET1 in the GCs was correlated with the tumor location (Table S3 , P = 0.036). Furthermore, down-regulation of IDH2 was positively correlated with the tumor classification N (P = 0.002) and the tumor stage (P = 0.027) ( Table 2 ). However, no significant association between TET2, TET3, TDG or IDH1 down-regulation and any of the clinicopathological factors was seen in our samples (data not shown).
5-hmC levels are correlated with TET1 gene expression
A linear regression analysis showed that TET1 expression was significantly and positively correlated with 5-hmC levels (P = 0.037, R = 0.428; Pearson's correlation coefficient). However, no correlation was seen between 5-hmC levels and the expressions of TET2, TET3, TDG, IDH1 or IDH2 in the gastric mucosa (Fig. 2) .
Comparison of 5-mC oxidation activities of TET1, TET2 and TET3 proteins in vitro
Expressions of TET1-3 were significantly decreased in GCs but only TET1 expression was notably correlated with 5-hmC levels. To further examine the relationships between 5-hmC and TET proteins in human cells we compared the 5-mC oxidation activities of the TET1, TET2 and TET3 proteins. Thus, full-length TET1, TET2 and TET3 plasmids were transfected in HEK293T cells. Then LC-MS/MS and real-time RT-PCR were used to quantitate the 5-hmC and gene expression levels in these cell lines. As shown in Fig. 3a , the forced expressions of TET1 and TET2 significantly increased the 5-hmC level (P \ 0.01) while TET3 moderately increased the 5-hmC level. Notably, TET1 had the highest efficiency in global DNA 5-mC oxidation among the TET family proteins.
Sequencing analysis of TET1-3 in the GCs
We were interested in whether 5-hmC reduction in tumors was associated with the somatic mutation of TET1-3 in GCs. [20] but their pathogenic significance was unclear. Since our sequencing study was performed using a relatively small number of available samples we decided to include the known functional variants Y1148* [21] and F1706fs*13 [22] in our transfection experiments.
Comparing 5-mC oxidation activity of 7 human TET2 variant proteins
We constructed and tested the 5-hmC-generating activities of TET2 catalytic domain (1123-2002 aa) variants in HEK293T cells identified in this study or in previous studies [21] [22] [23] . As shown in Fig. 3b , c, using the DNA dot blot and LC-MS/MS ( Figure S4 ), TET2 proteins obviously increased the number of 5-hmC adducts in human cells. The 5-mC oxidation activities of Y1148* [21] and F1706fs*13 [22] proteins were severely impaired but the functions of A1476V [21] , V1836M [21] , L1240V [23] , L1721W (newly found in this study) and I1762V (newly found in this study) proteins seemed to be retained. Moreover, LC-MS/MS data seems to be consistent with the results obtained from the dot blot analysis.
Discussion
Herein we applied LC-MS/MS for the quantification of 5-mC, 5-hmC, 5-fC, and 5-caC levels in both the tumorous and non-tumorous portions of human gastric mucosa resected. 5-mC was moderately decreased in GCs. 5-caC and 5-fC are also important metabolites of these dynamics of cytosine modification, as shown in Figure S1 . Considering reports on the existence of these molecules are limited in normal brain and brain tumor tissues [24, 25] our attempt was to first try to detect these modified cytosines in human non-neural tissue. We assumed that our detection limits were 0.103 fmol (5-fC) and 0.133 fmol (5-caC) based on calibration curves using internal controls; actually, no signal peaks were observed in human gastric tissues. Thus, we interpreted that there were no 5-fC and 5-caC in human gastric tissues. On the other hand, 5-hmC was reduced by about 3-fold in the tumors of GC cases. In line with recent studies [9, 26] , our data also show that 5-hmC values varied widely among individuals. P values were analyzed using a two-tailed Pearson correlation. P \ 0.05 was considered statistically significant GAPDH was used as a control; (c) Comparison of 5-mC oxidation activities of 7 variants of TET2 catalytic domain proteins using a DNA dot blot. Methylene blue staining was used as a total genomic DNA loading control. MB: methylene blue Interestingly, although 5-hmC levels were found to be generally decreased in GCs compared to gastric mucosa, the reduction in the tumor portion was inversely correlated with the progression of the tumor portion in cases with extensive lymph node metastasis. Reduction of 5-hmC in the tumors was less in cases where the tumor had invaded further (T4) than in cases where the tumors were limited to the mucosa (so-called early cancer T1). In short, T4 and N3 cases (progressive cases) had larger amounts of 5-hmC (Fig. 4 , P \ 0.05). The samples with stage I consistently had lower 5-hmC values than those with stage II and stage III ( Figure S5 , P \ 0.05). These findings together may suggest that the loss of 5-hmC in human GCs occurred in the early stage, at least in our cohort. More extensive studies using multiple cohorts will be needed to determine whether the loss of 5-hmC could become one of the markers representing some epigenetic nature of human gastric cancer in future.
Several enzymes influence DNA 5-hmC levels. To investigate the possible mechanism of 5-hmC reduction in GCs we quantified transcripts of 7 related genes using realtime RT-PCR. TET1-3, TDG and IDH2 were significantly reduced in the tumor portions in the GC cases. Downregulation of TET1 in particular was correlated with the tumor location of the GC. Surprisingly, down-regulation of IDH2 was positively correlated with the tumor N classification and the tumor stage; thus, IDH2 may play a role in the progress of GC. These findings are partially consistent with a recent study of melanoma. TET2 was capable of reestablishing the 5-hmC landscape in human melanoma cells. IDH2 increased the 5-hmC levels and prolonged tumor-free survival in a zebrafish melanoma model [11] . This evidence suggests that a deficiency of these enzymes may lead to one of the mechanisms of global 5-hmC reduction in GC. The next important finding was that the global 5-hmC levels were significantly and positively correlated with TET1 expression using a linear regression analysis, but not with TET2-3, TDG or IDH1-2. Additionally, our in vitro study confirmed that TET1 has the highest efficiency in global DNA 5-hmC modification in HEK293T cells among TET family genes. Together, the global loss of 5-hmC in GCs is mainly associated with the down-regulation of TET1 transcripts. Considering that all the TET family genes directly catalyze 5-mC to 5-hmC and that both TET2 and TET3 were down-regulated in our samples, we continue to speculate that TET2 and TET3 may also impact 5-hmC modifications in GCs, at least to some degree.
On the other hand, several known confounders are capable of changing 5-hmC levels in the human body; for example, vitamin C and hydroquinone are both capable of increasing 5-hmC levels in vitro [27, 28] . Lifestyle factors, such as food and medicine intake as well as cosmetics use, also cannot be excluded from factors that may influence the 5-hmC level in the human stomach. Estimations of the intake of particular diets based on a food frequency questionnaire and other descriptive methods used in epidemiology are often difficult, but a comprehensive analysis including lifestyle information will be a necessary challenge in this field.
According to previous literature [29] [30] [31] , down-regulation of IDH2 in GC may inhibits other 2-oxoglutaratedependent dioxygenases, particularly hypoxia-inducible factor (HIF) prolyl hydroxylases [29, 30] and the JmjC domain containing histone demethylases [31] . Thus, IDH2 down-regulation in gastric cancer may provide various insights regarding the biology of and therapeutic strategies for GCs.
Another finding, the down-regulation of TDG in gastric cancer, is likely to attract many investigators in the future. The functions of TDG, with the exception of its DNA glycosylase activity, are elusive and these functions are speculated to be relevant to p53 [32] and Wnt Signaling [33] .
Very recently, Yang et al. [12] reported that 5-hmC levels were markedly and negatively correlated with tumor invasion; that is, with the TNM stage and the number of lymph node metastases in GCs. They measured the 5-hmC level using a DNA dot blot assay and the down-regulation of TET1 transcripts was notably associated with a reduction of 5-hmC levels in GCs. The positive correlation between TET1 expression and 5-hmC levels found in our correlation analysis was consistent with their clinical findings and was reasonable considering the function of TET1. Some inconsistencies were present in that the correlation between the reduction of 5-hmC and progression indicators (N or T factors) of cancer was not clear in our subjects. This inconsistency might be related to the different analysis technologies, the limited number of cases, differences in the patient populations and other confounding factors. Our studies not only showed down-regulation of TET1 in our samples but also that of TET2, TET3, TDG and IDH2.
DNA mutation is another factor that influences protein activity. TET2 is mutationally inactivated in about 15 % of human myeloid cancers [34] . However, a few mutations of TET1-3 have been found in solid cancers and no somatic mutation in TET1-3 has been found to be associated with the loss of 5-hmC in our samples. Given that our sequencing study was performed using a relatively small number of available samples we also validated our findings using the Catalogue of Somatic Mutations in Cancer (COSMIC) [35] . As of January 31, 2014, the mutation rate of TET1 was 0 % (0/47), that of TET2 was 0 % (0/47) and that of TET3 was 2.23 % (1/47; p.L711L) in GCs.
Despite the small number of samples, our robust measurements of the DNA 5-hmC adduct and the in vitro analysis validated a decrease in 5-hmC in GCs, mainly due to TET1 down-regulation. In addition to the biological significance of TDG and IDH2 reduction in gastric cancer information on the local status of 5-hmC in the genome will be the next important topic of research on GCs in terms of acquired DNA changes, including adductomics [36] . Further studies in a larger cohort are required to evaluate the relationship among 5-hmC, TET1, IDH2 and clinical characteristic such as the stage of GC.
